A submitted premarket approval module and a granted Breakthrough Device designation are different regulatory milestones. Neither statement alone establishes that FDA has authorized a device for marketing. For ENT readers following implant and surgical technology, the task is to identify the milestone before interpreting its significance.
FDA describes a modular PMA as an application assembled through separate sections. Nonclinical, clinical and manufacturing information are examples of components that together form the complete application. An applicant can submit a finished module while compiling the rest. In a traditional PMA, the complete application arrives together.
The modular process starts with a customized submission plan, which FDA calls a shell. It identifies module contents and suggested timelines for the particular device. FDA reviews modules separately and provides feedback as they arrive. A reference to a 'second module' therefore cannot, by itself, identify the evidence submitted, what remains outstanding or when a decision will follow. Those questions require the surrounding record.
Under the PMA pathway, approval is a separate decision. FDA describes PMA as scientific and regulatory review to evaluate Class III devices. An applicant following that pathway must receive approval before marketing the device. FDA says the decision rests on sufficient valid scientific evidence that the device is safe and effective for its intended uses. Submitting information and receiving that decision are different events.
Breakthrough designation concerns an expedited development and review program. FDA describes opportunities for sponsor feedback and prioritized review, and allows a designation request before the marketing submission. The program includes devices pursuing PMA approval, 510(k) clearance or De Novo marketing authorization. FDA says designated devices still must meet its safety and effectiveness standards to receive marketing authorization. Designation does not replace that determination.
An announcement can preserve the exact milestone, its source and its date. A developer's submission announcement establishes what the developer says it submitted; it should not be rewritten as an agency approval. A report of a marketing decision needs the agency record for the particular device and intended use. Where the available record does not establish the next step or its timing, a launch forecast would go beyond the evidence.
This explainer examines FDA process descriptions observed October 14, 2026. Their original publication and update dates were not verified. It reports no new rule, designation or marketing decision, and makes no product-specific finding about clinical performance, treatment benefit, comparative outcomes or availability.
For an ENT practice assessing device news, a submission, an expedited-program designation and a marketing decision support different claims. Keeping the milestone precise helps readers identify what the record establishes and what still needs separate evidence.
Go to the source.
FDA PMA Application Methods ↗FDA Premarket Approval overview ↗FDA Breakthrough Devices Program ↗This methods explainer describes public reference records. It does not establish study results, a product’s current authorization or treatment suitability.
